CSL said that results from the trial showed that once-monthly subcutaneous injections of the first-in-class garadacimab significantly reduced the attack rate compared to placebo. …
CSL reports positive results from pivotal late-stage trial of first-in-class garadacimab
February 28, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News